These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


1565 related items for PubMed ID: 30213667

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. ERK Pathway in Activated, Myofibroblast-Like, Hepatic Stellate Cells: A Critical Signaling Crossroad Sustaining Liver Fibrosis.
    Foglia B, Cannito S, Bocca C, Parola M, Novo E.
    Int J Mol Sci; 2019 Jun 01; 20(11):. PubMed ID: 31159366
    [Abstract] [Full Text] [Related]

  • 3. Hepatic myofibroblasts and fibrogenic progression of chronic liver diseases.
    Novo E, Cannito S, Morello E, Paternostro C, Bocca C, Miglietta A, Parola M.
    Histol Histopathol; 2015 Sep 01; 30(9):1011-32. PubMed ID: 25896393
    [Abstract] [Full Text] [Related]

  • 4. Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis.
    Mallat A, Lotersztajn S.
    Am J Physiol Cell Physiol; 2013 Oct 15; 305(8):C789-99. PubMed ID: 23903700
    [Abstract] [Full Text] [Related]

  • 5. TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019.
    Dewidar B, Meyer C, Dooley S, Meindl-Beinker AN.
    Cells; 2019 Nov 11; 8(11):. PubMed ID: 31718044
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies.
    Parola M, Pinzani M.
    Mol Aspects Med; 2024 Feb 11; 95():101231. PubMed ID: 38056058
    [Abstract] [Full Text] [Related]

  • 12. Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C.
    Tanwar S, Rhodes F, Srivastava A, Trembling PM, Rosenberg WM.
    World J Gastroenterol; 2020 Jan 14; 26(2):109-133. PubMed ID: 31969775
    [Abstract] [Full Text] [Related]

  • 13. Hypoxia, hypoxia-inducible factors and fibrogenesis in chronic liver diseases.
    Cannito S, Paternostro C, Busletta C, Bocca C, Colombatto S, Miglietta A, Novo E, Parola M.
    Histol Histopathol; 2014 Jan 14; 29(1):33-44. PubMed ID: 23996844
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Myofibroblast - like cells and liver fibrogenesis: Emerging concepts in a rapidly moving scenario.
    Parola M, Marra F, Pinzani M.
    Mol Aspects Med; 2008 Jan 14; 29(1-2):58-66. PubMed ID: 18022682
    [Abstract] [Full Text] [Related]

  • 17. Pathophysiology of Liver Fibrosis.
    Pinzani M.
    Dig Dis; 2015 Jan 14; 33(4):492-7. PubMed ID: 26159264
    [Abstract] [Full Text] [Related]

  • 18. Liver fibrosis: a dynamic and potentially reversible process.
    Povero D, Busletta C, Novo E, di Bonzo LV, Cannito S, Paternostro C, Parola M.
    Histol Histopathol; 2010 Aug 14; 25(8):1075-91. PubMed ID: 20552556
    [Abstract] [Full Text] [Related]

  • 19. Hypoxia, Hypoxia-Inducible Factors and Liver Fibrosis.
    Foglia B, Novo E, Protopapa F, Maggiora M, Bocca C, Cannito S, Parola M.
    Cells; 2021 Jul 13; 10(7):. PubMed ID: 34359934
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 79.